Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

SIGN UP TO CONTINUEPrint Subscriber? Sign Up for Full Access!Please sign up for as low as 36 cents per day to continue ...

US stocks saw a decline on Monday as investors continued to unload key tech shares that have been driving the bull market.

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...

General Catalyst’s portfolio companies, starting with Aidoc and Commure, will use AWS’ services to build new artificial ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to ...

The company now expects revenue for 2025 to fall between $1.5 billion and $2.5 billion, a steep reduction from its previous ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

A statewide grand jury didn’t find evidence that COVID-19 vaccine manufacturers broke federal or state laws when making and ...